Literature DB >> 2179292

Therapy for cutaneous melanoma: an update.

V C Ho1, A J Sober.   

Abstract

This article reviews the current therapy for cutaneous melanoma. Diagnosis, staging, and prognostic evaluation, which are crucial to proper management, are discussed. Surgical excision is the treatment of choice for primary melanoma. The resection margins should be tailored to tumor thickness. Guidelines for surgery are presented. The controversy about elective regional lymph node dissections is discussed. Limb perfusion, chemotherapy, immunotherapy, radiotherapy, and hormonal therapy as adjuvant treatments of primary melanomas as well as the treatment of disseminated melanomas are reviewed and new developments are highlighted. Guidelines for the management of metastatic melanoma at various sites are given. Special issues such as "pregnancy/estrogen and melanoma" and "borderline melanoma" are discussed and approaches to these problems are suggested. Recommendations are given for the follow-up and counseling of patients with melanoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179292     DOI: 10.1016/0190-9622(90)70019-e

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  The detection and management of dysplastic nevi and early melanoma.

Authors:  J K Rivers
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

2.  Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma.

Authors:  D Schadendorf; B M Czarnetzki; B Wittig
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

3.  Metastatic malignant melanoma in a child.

Authors:  Y Jain; L S Arya; D Sarma
Journal:  Indian J Pediatr       Date:  1994 Mar-Apr       Impact factor: 1.967

4.  Common Skin Cancers: How to diagnose and treat them.

Authors:  V C Ho
Journal:  Can Fam Physician       Date:  1992-04       Impact factor: 3.275

5.  Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.

Authors:  D Schadendorf; M Worm; B M Czarnetzki
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

6.  Membrane transport proteins associated with drug resistance expressed in human melanoma.

Authors:  D Schadendorf; A Makki; C Stahr; A van Dyck; R Wanner; G L Scheffer; M J Flens; R Scheper; B M Henz
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

7.  Malignant melanoma in a black child: predisposing precursors and management.

Authors:  Olanrewaju T Adedoyin; Abdul-Wahab B R Johnson; Ayodele I Ojuawo; Enoch A O Afolayan; Kayode A Adeniji
Journal:  J Natl Med Assoc       Date:  2004-10       Impact factor: 1.798

8.  Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo.

Authors:  D Schadendorf; M A Kern; M Artuc; H L Pahl; T Rosenbach; I Fichtner; W Nürnberg; S Stüting; E von Stebut; M Worm; A Makki; K Jurgovsky; G Kolde; B M Henz
Journal:  J Cell Biol       Date:  1996-12       Impact factor: 10.539

9.  Long Noncoding RNA LINC02249 Is a Prognostic Biomarker and Correlates with Immunosuppressive Microenvironment in Skin Cutaneous Melanoma.

Authors:  Maotao Du; Liang Han; Pan Shen; Dengyan Wu; Shenghao Tu
Journal:  J Oncol       Date:  2022-09-07       Impact factor: 4.501

10.  Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.

Authors:  P Möller; Y Sun; T Dorbic; S Alijagic; A Makki; K Jurgovsky; M Schroff; B M Henz; B Wittig; D Schadendorf
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.